Roche Axes Phase II/III NSCLC Study as TIGIT Drug Loses to Keytruda-Chemo Combo

Published: Jul 08, 2024 By Tristan Manalac

Roche/iStock, HJBC

Pictured: Roche’s building in France/iStock, HJBC

Roche on Thursday announced that it will stop the Phase II/III SKYSCRAPER-06 study following disappointing data from its investigational anti-TIGIT antibody tiragolumab, which was unable to significantly improve survival in patients with non-small cell lung cancer.

The pivotal study, which enrolled 524 patients with non-squamous non-small cell lung cancer (NSCLC), tested an investigational regimen combining tiragolumab with Roche’s PD-L1 blocker Tecentriq (atezolizumab) in the first-line setting. For the control, the pharma used a combination of Merck’s Keytruda (pembrolizumab) and chemotherapy.

At the time of the primary analysis, the tiragolumab regimen showed “reduced efficacy” in progression-free survival (PFS) with a hazard ratio of 1.27 in favor of the Keytruda arm. Overall survival (OS) data, which were not mature at the time of the analysis, also…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks